HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden dex bill expected

This article was originally published in The Tan Sheet

Executive Summary

A bill from Sen. Joe Biden, D-Del., that would place an age restriction of 18 on OTC sales of dextromethorphan is likely to be introduced before the August recess. The bill will not include language establishing pre-emption over potential state bills with greater restrictions, according to staffers, but will include funding for abuse prevention education efforts. Biden has worked with input from manufacturers and retailers (1"The Tan Sheet" March 12, 2007, p. 3). The bill will also address abuse of bulk DXM...

You may also be interested in...



Will Oklahoma Dextromethorphan Age Restriction Bill Lead The Way?

Increasing momentum in states for age restrictions on sales of dextromethorphan-containing cough/cold products could drive retail industry support for a federal bill mandating a uniform, nationwide age restriction

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel